FDA Regs Plunged in 2017 But Other Developments Built on Trends

Drug GMP Report
A A
Although 2017 saw significantly fewer new FDA regulations, other regulatory and enforcement activities at the agency built on existing long-term trends, according to a new report from PriceWaterhouseCoopers (PwC).

To View This Article:

Login

Subscribe To Drug GMP Report